demonstrated that activation of PPARγ by a black-phosphorus-based agonist overcame gemcitabine resistance in pancreatic adenocarcinoma by suppressing cancer stemness and downregulating resistance-related biomarkers (30). This evidence concerns the gene PPARG and pancreatic adenocarcinoma.